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 2 
ABSTRACT 33 
We have recently demonstrated that C57BL/6NTac and C57BL/6JRj substrains are 34 
significantly different in their response to high fat diet induced obesity (DIO). The C57BL/6JRj 35 
substrain seems to be protected from DIO and genetic differences between C57BL/6J and 36 
C57BL/6N substrains at 11 SNP loci have been identified. To define genetic variants as well 37 
as differences in parameters of glucose homeostasis and insulin sensitivity between 38 
C57BL/6NTac and C57BL/6JRj substrains which may explain the different response to DIO, 39 
we analysed 208 first backcross (BC1) hybrids of C57BL/6NTac and C57BL/6JRj 40 
[(C57BL/6NTacxC57BL/6JRj)F1xC57BL/6NTac] mice. Body weight, epigonadal and 41 
subcutaneous fat mass, circulating leptin, as well as parameters of glucose metabolism were 42 
measured after 10 weeks of high fat diet (HFD). Genetic profiling of BC1 hybrids were 43 
performed using TaqMan SNP genotyping assays. Furthermore, to assess if SNP 44 
polymorphisms could affect mRNA level, gene expression analysis was carried out in murine 45 
liver samples. Human subcutaneous adipose tissue was used to verify murine data of 46 
SNAP29. We identified four gender-specific variants which are associated with the extent of 47 
HFD induced weight gain and fat depot mass. BC1 hybrids carrying the combination of risk 48 
or beneficial alleles exhibit the phenotypical extremes of the parental strains. Murine and 49 
human SC expression analysis revealed Snap29 as strongest candidate.  50 
Our data indicate an important role of these loci in responsiveness to HFD induced obesity 51 
and suggest genes of the synaptic vesicle release system such as Snap29 being involved in 52 
the regulation of high fat DIO. 53 
 54 
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 3 
Background 59 
Experimental animal models offer a great opportunity to overcome heterogeneity and various 60 
environmental factors influencing obesity and associated disorders. The C57BL/6J strain is 61 
the single most widely used inbred strain and its genome has been extraordinarily well 62 
categorized with the most complete sequence data available produced by the Mouse 63 
Genome Sequencing Consortium (33, 48). C57BL/6J mice have been extensively used as a 64 
control strain in the study of metabolic diseases or diet induced obesity (DIO) as well as 65 
background strain for transgenic and knockout mice (10). And while often different substrains 66 
are treated as identical (referred to as C57 or B6), determination of the exact background is 67 
essential when examining the genotype due to potential background effects on the 68 
phenotype. It is well known, that the genetic background influences the phenotype as 69 
demonstrated for the ob/ob mutation showing large differences in diabetes susceptibility on 70 
BTBR and C57BL/6J genetic backgrounds (43). Recently it was reported that mispairing of 71 
different C57BL/6 substrains can lead to a significant bias of results (5), reiterating the 72 
importance of the genetic background when designing and studying genetically engineered 73 
mice. Many recent studies reported phenotypical and genetic differences among B6J 74 
substrains (4, 8). In particular, differences in behavior (19, 40), alcohol and drug 75 
responsiveness (12, 18, 32) as well as glucose homeostasis (46) have been reported.  76 
One extensively studied genetic difference between C57BL/6J and C57BL/6N mice was 77 
found in the nicotinamide nucleotide transhydrogenase (Nnt) gene on chromosome 13. In the 78 
C57BL/6J strain, a missense (methionine to threonine) mutation, in combination with the in-79 
frame 5 exon deletion mutation (eliminating four putative transmembrane helices) results in a 80 
truncated Nnt variant and markedly lower Nnt protein expression in liver and islets (14, 46). 81 
Nnt activity has been linked to impaired glucose metabolism and insulin secretion (13, 46).  82 
Recent genotyping of single nucleotide polymorphisms (SNPs) identified further genetic 83 
differences between C57BL/6J and C57BL/6N substrains at 11 loci (24, 31, 51). One SNP 84 
was found between C57BL/6J substrains while no genetic differences were detected among 85 
C57BL/6N substrains (31, 51). Five of the eleven loci map within known genes. The 86 
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genotype of fibroblast growth factor 14 (Fgf14), LIM and senescent cell antigen-like 87 
domains 1 (Lims1), amyloid precursor-like protein 2 (Aplp2) and soluble n-ethylmaleimide 88 
sensitive factor attachment protein 29 (Snap29) differs between C57BL/6N and C57BL/6J 89 
strains and a SNP associated with N-acetylated alpha-linked acidic dipeptidase-like 2 90 
(Naaladl2) between certain C57BL/6J substrains. 91 
Studies on high fat diet induced obesity revealed differences between core substrains 92 
C57BL/6NTac and C57BL/6JRj regarding their response to a HFD and the development of 93 
DIO (36). Recently, we reported phenotypical differences under HFD conditions between 94 
C57BL/6NTac and C57BL/6JRj substrains and found that the C57BL/6JRj strain is protected 95 
against DIO independently of physical activity and food intake (24).  96 
To define the causal genetic differences which may underlie and explain the varying HFD 97 
responsiveness and DIO manifestation in C57BL/6J and C57BL/6N mice, we genetically and 98 
phenotypically characterized first backcross (BC1) hybrids of C57BL/6NTac and C57BL/6JRj 99 
mice [(C57BL/6NTacxC57BL/6JRj)F1 x C57BL/6NTac]. In addition, to assess if SNP 100 
polymorphisms could affect mRNA levels, real-time based gene expression analysis was 101 
carried out in murine liver samples and human subcutaneous adipose tissue.   102 
 103 
MATERIAL AND METHODS 104 
Animals and phenotyping. In 2007, breeding pairs from Taconic Farms, Inc. 105 
(C57BL/6NTac; Hudson, New York, USA) and from Janvier (C57BL/6JRj; Le Genest Saint 106 
Isle, France) were obtained and bred in our animal facility under standardized environmental 107 
conditions. C57BL/6NTac mice were crossed with C57BL/6JRj and the 108 
(C57BL/6NTacxC57BL/6JRj)F1 hybrids were backcrossed onto C57BL/6NTac to generate 109 
first backcross hybrids (BC1). F1 hybrids (N=20 Female/Male 10/10) and all backcross 110 
hybrids (N= 208; Female: N=99, Male: N=109) were fed a diet containing 58% fat in total 111 
calories with sucrose (E15772-34, Ssniff, Soest, Germany; composition equals D12331 112 
(Research Diets, New Brunswick, NJ, USA) as fed in (22)) for 8 weeks beginning at 4 weeks 113 
of age. All animals were kept in groups of 4 in Macrolon cages (Size 2, Ehret GmbH, 114 
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Emmerdingen Germany) in the same room and had free access to food and water. Body 115 
weight was recorded weekly and at the end of observation period liver weight, visceral fat 116 
mass, subcutaneous fat mass and HbA1c (%) were measured. Blood samples were obtained 117 
after sacrifice. Serum leptin as well as insulin concentrations were measured using 118 
commercially available ELISA kits (Crystal Chem, Downers Grove, IL). Organs and fat 119 
depots were weighed and organ or depot mass was related to whole body mass to obtain 120 
relative organ or depot weights, respectively. 121 
All experiments were conform to the Guide for the Care and Use of Laboratory Animals 122 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) 123 
and were approved by the local authorities (Regierungspräsidium Leipzig) of the state of 124 
Saxony, Germany, as recommended by the responsible local animal ethics review board. 125 
SNP genotyping. DNA was extracted from tail tips using the DNeasy kit (Qiagen, Hilden, 126 
Germany). SNP genotyping was done using the TaqMan SNP Genotyping assay according 127 
to the manufacturer's protocol (Applied Biosystems Inc., Foster City, CA). To assess 128 
genotyping reproducibility, a random 5% selection of the sample was re-genotyped for all 129 
SNPs; all genotypes matched initial designated genotypes. Furthermore, genomic DNA from 130 
F1 hybrids and parental strains served as controls. Call rates of all SNPs ranged from 98 to 131 
100%. 132 
Expression analysis. Total RNA was isolated from snap-frozen liver (N=7 per genotype) 133 
and subcutaneous adipose tissue (N=6 per genotype) samples using RNeasyMini Kit 134 
(Qiagen, Hilden, Germany). RT-PCR was performed with the TaqMan 7500 system (ABI, 135 
Darmstadt, Germany). 36B4 was used as an internal reference. The following primers were 136 
used: Snap29 5´-AGGCTACAGGATGCAGAACTAGACT-3´ (forward) and 5´-137 
TGTCATCCTGTTCCTCAATTTCT -3´ (reverse); Aplp2 5´-CCGAATGGACAGGGTAAAGA-3´ 138 
(forward) and 5´-CACAAGCTGCTGCTTCTCAC-3´ (reverse); Lims1 5´-139 
GGAGCTGAAAGGGGAGCTAT-3´ (forward) and 5´- TGCCCAAGAAATGGTTTTTC-3´ 140 
(reverse); Snca 5´-CAGAGGCAGCTGGAAAGACA-3´ (forward) and 5´-141 
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CACCACTGCTCCTCCAACAT-3´ (reverse). Relative gene expression was calculated using 142 
the standard curve method.  143 
Human subjects. Subcutaneous adipose tissue was obtained from 234 Caucasian men (N = 144 
84) and women (N = 150) who underwent open abdominal surgery for cholecystectomy, 145 
appendectomy, weight reduction surgery, abdominal injuries or explorative laparotomy 146 
(Table 4). The age ranged from 18 to 89 years and body mass index from 14.1 to 71.0 kg/m2. 147 
Sixty nine subjects had type 2 diabetes. All subjects had a stable weight with no fluctuations 148 
of more than 3% of the body weight for at least three months before surgery. Patients with 149 
severe conditions including generalized inflammation or end stage malignant diseases were 150 
excluded from the study. Samples of visceral and subcutaneous adipose tissue were 151 
immediately frozen in liquid nitrogen after explantation. The study was approved by the 152 
Ethics Committee of the University of Leipzig (Germany). All subjects gave written informed 153 
consent before taking part in the study. 154 
Measures of body fat content. BMI was calculated as weight (in kg) divided by the square 155 
of height (in m). Waist and hip circumferences were measured, and the WHR was calculated. 156 
Percentage body fat was measured by dual-energy X-ray absorptiometry (DEXA). In 157 
addition, abdominal visceral and subcutaneous fat areas were calculated using computed 158 
tomography (CT) scans at the level of L4–L5 (1). 159 
Analysis of human SNAP29 gene expression. Human SNAP29 mRNA was measured by 160 
quantitative real-time RT-PCR using the TaqMan assay (Hs00191150_m1) and 161 
hypoxanthine guanine phosphoribosyltransferase (HPRT, Hs01003267_m1)  as house-162 
keeping gene and fluorescence was detected on an ABI PRISM 7000 sequence detector 163 
(Applied Biosystems, Darmstadt, Germany). Human SNAP29 gene expression was 164 
determined by the standard curve method and normalized to the house-keeping gene HPRT 165 
as previously described (25, 30). 1 g of total RNA (TRIzol Reagent by Life Technologies, 166 
Grand Island, NY) from paired subcutaneous and visceral adipose tissue samples was 167 
reverse transcribed with standard reagents (Life Technologies, Grand Island, NY) as shown 168 
elsewhere (25, 30). Quantitative real-time reverse transcription-PCR was performed for each 169 
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sample in duplicate with total RNA, 1×TaqMan Universal Master Mix no AmpErase UNG, 170 
6.25 units of murine leukemia virus reverse transcriptase (both from Applied Biosystems) and 171 
gene-specific primers-probe sets, using an ABI PRISM 7500 sequence detector (Applied 172 
Biosystems). cDNA samples were incubated in the ABI PRISM 7500 sequence detector for 173 
an initial denaturation at 95°C for 10 min, followed by 40 PCR cycles, each cycle consisting 174 
of 95°C for 15 s, 60°C for 1 min, and 72°C for 1 min. Accuracy of RNA quantitation was 175 
optimized by gene-specific primer-probe sets that span intron-exon boundaries. The 176 
specificity of the PCR was further verified by subjecting the amplification products to agarose 177 
gel electrophoresis. 178 
Data analysis and statistics. Data are given means ± SD. Datasets were analyzed for 179 
statistical significance using a two-tailed unpaired t test, or differences were assessed by 180 
one-way ANOVA using the Statistical Package for Social Science, version 20.0 (SPSS, 181 
Chicago, IL). All data are presented without correcting for multiple testing (38). To consider 182 
the findings significant, Bonferroni corrections for multiple testing would require a P-value of 183 
0.005 (0.05 divided by the number of SNPs) for the SNP analyses and a P-value of 0.01 184 
(0.05 divided by the number of considered genes) for the eQTL analyses.  185 
 186 
187 
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 188 
RESULTS 189 
DIO responsiveness of the F1 hybrids. The DIO responsiveness of the F1 hybrids (Fig 1A) 190 
revealed an intermediate response to the HFD between the DIO phenotypes of parental 191 
strains, indicating a polygenic cause of the observed DIO resistance in the C57BL/6JRj strain 192 
(24). As expected, all eleven SNP genotype distributions were obtained with the expected 193 
Mendelian frequency of 50 percent (Table 1). In a gender specific manner, BC1 hybrids 194 
indicated significant associations of SNPs rs13480122 (Aplp2), rs13481014, rs13478783 and 195 
rs4165065 (Snap29) with manifestation of DIO (Table 1). In males, we detected a significant 196 
association between rs13480122 (Aplp2) and a suggestive association rs13481014 between 197 
and body weight gain under HFD conditions. Male carriers of homozygous alleles of SNP 198 
rs13481014 (C/C) responded more pronounced to the HFD after 6 weeks of HFD while 199 
homozygous carriers of rs13480122 (C/C) featured significantly less body weight from 200 
beginning to end of the HFD. Homozygous carriers of rs13480122 (C/C) were already 201 
significantly leaner at the beginning of the HFD (Table 1). With respect to fat mass 202 
distribution under HFD, relative fat depot masses were suggestively associated with 203 
rs13480122 (C/C) and rs4165065 (C/C). In accordance to the body weight gain 204 
characteristics, homozygous carriers of rs13480122 (C/C) had a tendency for lower 205 
epigonadal and significantly lower subcutaneous fat mass. Male mice with the homozygous 206 
variant of SNP rs13481014 (C/C) had both lower epigonadal and subcutaneous adipose 207 
tissue mass (nominal p-value <0.05) (Table 2).  208 
For female BC1 mice, homozygous carriers of SNPs rs13478783 (G/G) as well as 209 
rs4165065 (C/C) gained less weight after 8 weeks of HFD (Table 1), but exhibited only a non 210 
significantly lower epigonadal fat mass compared to heterozygous littermates (Table 2).  211 
For both genders, we found suggestive/nominal associations between rs13478783 (G/G), 212 
rs13481014 (C/T) and lower serum leptin levels (Table 2). Additionally and only in males 213 
rs13478783 (G/G) was associated with lower serum insulin concentrations (nominal p-value 214 
<0.05) (Table 2). Combinations of respective beneficial or risk alleles (beneficial allele 215 
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combinations: male mice: (C/C) of rs13480122 and (C/T) of rs13481014; female mice: (G/G) 216 
of rs13478783 and (C/C) of rs4165065) result in an additive and even stronger effect on the 217 
extent of DIO manifestation both in male and female carriers (Table 1 and 2, Fig 1B, C).  218 
Gene expression analysis. As mentioned, five of the eleven loci map within known genes. 219 
Therefore, we performed gene expression analysis of those known genes to elucidate if the 220 
SNP genotype affects mRNA levels. Here we detected an association between genotype and 221 
expression levels for Snap29 (Fig 2A). Different levels of expression between genotypes 222 
were obtained in liver and subcutaneous adipose tissue samples for the Snap29 gene (Fig 223 
2A, B). In BL/6JRj mice Snap29 mRNA expression is significantly higher than in BL/6NTac 224 
mice. Since Snap29 seemed to be the strongest candidate in the murine model, we analyzed 225 
SNAP29 expression in subcutaneous human adipose tissue. Comparison of SNAP29 mRNA 226 
expression in subgroups of BMI <25 or >30kg/m² revealed significantly lower subcutaneous 227 
SNAP29 mRNA expression in the obese subgroup (Fig 2C). Univariate correlation analysis 228 
of the entire study population (N=234) identified significant correlations between 229 
subcutaneous SNAP29 gene expression and BMI (r=-0.267; p<0.001), % body fat (r=-0.241; 230 
p=0.002), CT ratio (r=0.204; p=0.004), waist and hip circumferences (waist: r=-0.268; 231 
p<0.001; hip: r=-0.063; p<0.001), subcutaneous and visceral fat area (sc: r= -0.265; p<0.001; 232 
vis: r=-0.217; p=0.002) as well as fasting plasma insulin (r=-0.211; p=0.005) and leptin serum 233 
concentrations (r=-0.258; p=0.001) (Table 3). After adjusting for age, gender and BMI, only 234 
CT ratio (r=0.191; p=0.032) remained suggestively associated with subcutaneous SNAP29 235 
mRNA expression. 236 
 237 
DISCUSSION 238 
We found that the C57BL/6JRj substrain from Janvier differed at 11 SNPs from the 239 
C57BL/6NTac substrain as it has been reported for other C57BL/6J substrains (24, 31). SNP 240 
rs13477019 within the Naaladl2 gene represents a unique allele found in some C57BL/6J 241 
strains (31, 51). The C57BL/6JRj strain shares the same rs13477019 allele as C57BL/6N 242 
substrains (A) and thus differs from the “original” C57BL/6J (Jackson Labs or Charles River) 243 
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strain (T-allele), as it has been reported for two C57BL/6J substrains commonly used in 244 
Japan (C57BL/6JJcl and C57BL/6JmsSlc) (31). The Japanese substrains C57BL/6JJcl and 245 
C57BL/6JmsSlc were separated from the C57/BL/6J strain from The Jackson Laboratory in 246 
the late 1980s (1989 and 1987) and C57BL/6JRj mice were transferred from Centre de 247 
Service des Animaux de Laboratoire (Orleans, France) to Janvier at F172 in 1993, according 248 
to the Janvier product catalog. The strain has been frequently used in various studies as 249 
control and background strain for knock-out mice (2, 3, 6, 23, 28, 29).  250 
We have recently demonstrated that substrains of C57BL/6, C57BL/6NTac and C57BL/6JRj 251 
have a heterogeneous responsiveness to HFD and manifestation of DIO (24). These data 252 
support previous findings of gender- and substrain-related differences in the response to DIO 253 
in C57BL/6NJ mice and C57BL/6J mice (both from Jackson Laboratory) (36). In addition, 254 
DIO was dependent on the diet itself (36). Under a high fat diet (60% of calories), C57BL/6J 255 
mice gained significantly more weight, while under a moderate fat diet (10% of calories) 256 
C57BL/6NJ mice outgained their C57BL/6NJ counterparts (36).  257 
Since different response to DIO between C57BL/6JRj and C57BL/6N mice could not be 258 
explained by increased physical activity or differences in food intake, we investigated the 259 
impact of the identified eleven SNPs on manifestation of DIO by generating first backcross 260 
hybrids [(C57BL/6NTacxC57BL/6JRj)F1xC57BL/6NTac].  261 
Here, we demonstrate that 4 SNPs (rs13481014, rs13480122 (Aplp2), rs13478783, 262 
rs4165065 (Snap29) differing between C57BL/6NTac and C57BL/6JRj are associated with 263 
body weight gain under HFD in a gender specific manner (Table 1). Furthermore and 264 
reflecting the HFD induced body weight gain differences, relative fat depot mass was 265 
associated with SNPs rs13480122, rs13481014 and rs4165065 (nominal p-value <0.05). In 266 
both genders, we found suggestive associations between rs13478783, rs13481014 and 267 
serum leptin levels and additionally rs13478783 showed effects on serum insulin levels in a 268 
gender specific manner (Table 2). 269 
Since rs13481014 obviously maps within a “gene desert”, functional consequences and links 270 
to DIO are elusive. However,  rs13480122 is mapping within the Aplp2 gene, which has been 271 
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linked to glucose homeostasis and growth (35). Amyloid precursor like-protein 2 (Aplp2) 272 
belongs to the amyloid precursor protein (APP) family together with Aplp1 and APP, with 273 
APP representing the source of the neurotoxic amyloid ȕ peptide involved in Alzheimer’s 274 
disease (17). Knockout mice studies have shown that single disruptions of App, Aplp1, or 275 
Aplp2 only caused minor abnormalities (20, 47, 50) While Aplp2-/-/App-/- mice and Aplp2-/-276 
/Aplp1-/- both showed a lethal phenotype, Aplp1-/-/App-/- mice were viable (20) and triple 277 
knockout mice showed a 100% lethal phenotype (21). These results suggest that APLP2 278 
exhibits a key physiological role among the mammalian APP family members. Functions of 279 
APP family proteins and especially APLP2 are poorly understood. Aplp2 deficiency in mice 280 
(Aplp2-/-) results in  significantly lower body weight, lower plasma glucose and increased 281 
plasma insulin levels in 13 weeks old  Aplp2-/- mice compared to control mice (C57BL/6J x 282 
129/Sv) (35). In contrast to that, Koch et al. reported Aplp2-/- mice to be normal in size and 283 
healthy up to 22 months of age in the original publication on the generation of the Aplp2-/- 284 
model and mice had the same genetic backgrounds in both studies (47). Noteworthy, 285 
besides resistance to HFD induced weight gain, we found male BC1 hybrids homozygous for 286 
rs13480122 (C/C) already significantly lighter than heterozygous (C/T) allele carriers at 4 287 
weeks of age before the switch to the HFD (Table 1) indicating a diet independent effect of 288 
this variant on body weight possibly related to altered Aplp2 gene activity. 289 
In addition, SNP rs4165065 exhibiting a female specific effect on DIO is mapping within the 290 
Snap29 gene which has been linked to cerebral dysgenesis, neuropathy, ichthyosis and 291 
keratoderma (CEDNIK) syndrome and schizophrenia (15, 39, 42). Soluble n-ethylmaleimide 292 
sensitive factor attachment protein (SNAP) 29 is a member of the SNAP receptor (SNARE) 293 
family of proteins which are required for vesicle trafficking and thus are essential in 294 
numerous physiological processes (7, 49). SNARE proteins seem to be mainly responsible 295 
for mediating fusion between vesicles and their target membrane (11).Two loss of function 296 
mutations in the Snap29 gene result in the neurocutaneous CEDNIK syndrome in humans 297 
(15, 42). On the molecular level, the loss of SNAP29 resulted in impaired recycling of 298 
transferrin and ȕ1-integrin demonstrating the importance of SNAP29 mediated membrane 299 
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fusion in endocytic recycling and consequently cell motility (37). It has been reported, that 300 
SNAP29 is present at synapses and inhibits disassembly of the SNARE complex and seems 301 
to modulate synaptic transmission and postfusion recycling of SNARE components (44).  302 
SNP rs13478783 is located 150kb upstream of the alpha synuclein (Snca) gene. SNCA, is 303 
primarily known for its prominent role as molecular hallmark of several neurodegenerative 304 
conditions such as Parkinson’s disease now termed synucleinopathies (41). There is strong 305 
evidence on the role of SNCA in the regulation of synaptic-vesicle release and indicate a 306 
stabilising effect on complexes of SNARE family proteins (9, 26, 34). In this context, SNCA 307 
has been shown to be a cytoplasmic ligand of the insulin-secretory granule and to interact 308 
with KATP channels and in consequence exhibited an inhibitory action on insulin secretion 309 
(16). Exogenous overexpression of Į-synuclein inhibited insulin secretion in INS1-832/13 310 
cells, while loss of SCNA expression potentiated insulin secretion in SNCA deficient ASKO 311 
islets (16). Additionally, recent studies demonstrated inflammatory stimuli induced SNCA 312 
expression in macrophages and an SNCA inherent ability of macrophage activation 313 
depending on N-terminal and C-terminal domains of the protein (27, 45). A possible 314 
regulatory role of SCNA in processes of inflammation might present a link between SCNA 315 
and adipose tissue and obesity, as obesity is well established as a state of systemic and 316 
chronic, low-grade inflammation.  317 
To assess if SNP differences could affect Snap29, Aplp2, Snca expression, we performed 318 
real-time based gene expression from C57BL/6JRj, C57BL/6NTac and heterozygous mice in 319 
liver samples. Here we detected that Snap29 mRNA is significantly up-regulated in liver and 320 
adipose tissue of C57BL/JRj mice, indicating association between genotype and mRNA 321 
level. Since, Snap29 seems to have strongest effects in mice; we performed gene 322 
expression analysis in subcutaneous human adipose tissue as well. Comparison of SNAP29 323 
mRNA expression in subgroups of BMI <25 or >30kg/m² revealed significantly lower SC 324 
SNAP29 mRNA expression in the obese subgroup (Fig 2B), indicating an association 325 
between SNAP29 mRNA level and measures of obesity. Univariate correlation analyses of 326 
the entire study population identified significant correlations primarily related to parameters of 327 
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obesity and fat distribution. These correlations did not remain significant after adjusting for 328 
age, gender and BMI and correcting for multiple testing. These expression data suggests a 329 
potential role of SNAP29 in manifestation of obesity and or DIO.  330 
Conclusion 331 
In summary, we have identified gender specific SNPs between C57BL/6NTac and 332 
C57BL/6JRj substrains which are associated with body weight gain and relative fat depot 333 
mass under HFD in first backcross hybrids of C57BL/6NTac and C57BL/6JRj mice 334 
[(C57BL/6NTacxC57BL/6JRj)F1 x C57BL/6NTac]. For the SNPs mapping within or nearby 335 
known genes, Aplp2, Snap29 and Snca all are involved in severe neurodegenerative or 336 
neurocutaneous diseases or syndromes. Gene expression analysis in mice and human 337 
tissue identified Snap29 as strongest candidate for parameters related to obesity and fat 338 
distribution. And although knowledge and understanding of molecular functions of these 339 
genes are in general limited, SNP concerning genes reported in this study as associated with 340 
manifestation of DIO all have certain common functional ground as being involved in synaptic 341 
vesicle release and SNARE complex stability.  342 
Our data demonstrate that DIO responsiveness is associated with genetic disparity between 343 
C57BL/6NTac and C57BL/6JRj substrains and suggests genes of the synaptic vesicle 344 
release system being involved in the regulation of high fat DIO.  345 
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Figure legends 566 
 567 
Figure 1. Manifestation of high fat diet induced obesity in parental substrains, F1 and 568 
BC1 hybrids. Body weight gain of parental C57BL/6JRj and C57BL/6NTac in comparison 569 
with F1 mice (females, 6 week HFD) (A) or in comparison with beneficial or risk alleles 570 
carrying BC1 hybrids (male mice;8 week HFD) (B). Body weight of male parent C57BL/6JRj 571 
and C57BL/6NTac as well as BC1 carriers of beneficial and risk alleles after 8 weeks under 572 
HFD (C). Beneficial allele combination: (C/C) of rs13480122 (Aplp2) and (C/T) of 573 
rs13481014; risk allele combination: (C/T) of rs13480122 (Aplp2) and (C/C) of rs13481014. 574 
Data is presented as mean ± SD. 575 
Figure 2. Relative gene expression analysis in mouse liver (A) and subcutaneous 576 
adipose tissue (B) of Snap29, Snca, Aplp2 in different genotypes and SNAP29 mRNA 577 
levels in human subcutaneous adipose tissue (C). Results present means ± SE from n=6 578 
liver and subcutaneous adipose tissue samples per genotype. Results present means ± SE 579 
from lean subjects, N=44 vs. obese subjects, N=190. * P<0.01 and ** P<0.001 indicate 580 
statistical significance after Bonferroni corrections for multiple testing. AU, arbitrary units. 581 
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Table 1. High fat diet induced body weight gain in backcross hybrids and parental control strains.  
 
SNP or strain Chr. Sex Genotype N Body weight  (g)
     week 4 week 6 week 8 week 10 week 12
rs13480122 
(Aplp2) 
9 m homo (C/C) 52 13.7 ± 2.3# 21.4 ± 1.6* 25.3 ± 2.6# 29.5 ± 3.4# 33.4 ± 4.1#
  het (C/T) 55 15.1 ± 2.4 22.1 ± 1.4 26.8 ± 2.4 31.4 ± 3.2 35.6 ± 3.8
rs13481014 
 
11 m homo (C/C) 47 14.1 ± 2.3 22.0 ± 1.5 26.6 ± 2.1 31.3 ± 3.2* 35.6 ± 3.8**
  het (C/T) 62 14.8 ± 2.5 21.7 ± 1.6 25.6 ± 2.6 29.8 ± 3.3 33.6 ± 4.1
          
allele 
combination 
 m beneficial 30 13.9 ± 2.3 21.2 ± 1.6* 24.8 ± 2.7** 28.9 ± 3.5** 32.6 ± 4.5**
  risk 25 14.6 ± 2.2 22.1 ± 1.4 27.1 ± 2.5 32.2 ± 3.2 36.6 ± 3.9
          
C57BL/6JRj  m  9 14.9 ± 2.3 21.6 ± 2.0 25.7 ± 2.7 29.2 ± 3.4* 33.6 ± 3.8*
C57BL/6NTac  m  10 14.3 ± 2.4 22.0 ± 2.5 27.2 ± 2.6 32.4 ± 2.9 37.2 ± 3.1
          
          
rs13478783 
(Snca) 
6 f homo (G/G) 46 12.8 ± 1.6 17.6 ± 1.2 19.8 ± 1.3* 22.2 ± 1.9** 25.0 ± 3.0*
  het (G/A) 53 12.7 ± 1.8 17.9 ± 1.4 20.4 ± 1.8 23.5 ± 2.7 26.6 ± 3.6
rs4165065 
(Snap29) 
10 f homo (C/C) 48 12.8 ± 1.6 17.5 ± 1.3 19.8 ± 1.5* 22.4 ± 2.1* 25.2 ± 3.0*
  het (C/T) 49 12.6 ± 1.9 18.0 ± 1.3 20.5 ± 1.7 23.4 ± 2.7 26.6 ± 3.6
          
allele 
combination 
 f beneficial 24 12.9 ± 1.5 17.4 ± 1.2 19.6 ± 1 4* 21.9 ± 1.9** 24.6 ± 3.0**
  risk 29 12.6 ± 2.0 18.1 ± 1.4 20.8 ± 3.0 24.0 ± 3.0 27.3 ± 3.9
          
C57BL/6JRj  f  6 13.4 ± 1.5 18.6 ± 1.6 20.5 ± 1.6 22.5 ± 2.2 24.5 ± 2.7
C57BL/6NTac  f  6 13.1 ± 1.8 18.3 ± 1.6 20.8 ± 2.0 23.8 ± 3.0 27.8 ± 3.3
Data represent means ± SD. *suggestive association between genotype variants (uncorrected p-values at *0.05, **0.01 level). # significant association between 
genotype variants (p-values < #0.005). homo: homozygous; het: heterozygous. beneficial allele combination: male mice:(C/C) of rs13480122 and (C/T) of 
rs13481014; female mice: (G/G) for rs13478783 and (C/C) for rs4165065; risk allele combination: male mice: (C/T) for rs13480122 and (C/C) for rs13481014; 
female mice: (G/A) for rs13478783 and (C/T) for rs4165065; 
 
 
Table 2. Specific organ masses and fasting serum concentrations in BC1 hybrids and parental control strains. 
 
SNP or strain Chr. Sex Genotype N Tissue weight (% from body weight) Fasting serum levels
     liver epi sc leptin (ng/ml) insulin (ng/ml)
rs13478783 
(Snca) 
6 m homo (G/G) 59 3.8 ± 0.4 4.9 ± 1.1 2.6 ± 0.6 14.0 ± 6.5* 1.03 ± 0.48*
  het (G/A) 50 3.7 ± 0.4 5.0 ± 1.0 2.7 ± 0.6 16.8 ± 7.5 1.37 ± 0.84
rs13480122 
(Aplp2) 
9 m homo (C/C) 52 3.7 ± 0.3 4.7 ± 1.1 2.5 ± 0.5* 14.3 ± 6.7 1.08 ± 0.56
  het (C/T) 55 3.8 ± 0.5 5.1 ± 1.0 2.8 ± 0.7 16.2 ± 7.5 1.30 ± 0.79
rs13481014 
 
11 m homo (C/C) 47 3.8 ± 0.5 5.3 ± 1.0** 2.8 ± 0.6* 17.0 ± 6.4* 1.19 ± 0.62
  het (C/T) 62 3.8 ± 0.3 4.7 ± 1.0 2.6 ± 0.7 14.0 ± 7.3 1.18 ± 0.74
          
allele 
combination 
 m beneficial 30 3.8 ± 0.3 4.5 ± 1.1** 2.5 ± 0.6** 13.0 ± 7.2* 1.12 ± 0.60
  risk 25 3.9 ± 0.6 5.5 ± 1.0 3.0 ± 0.6 17.9 ± 7.0 1.34 ± 0.68
          
C57BL/6JRj  m  9 3.7 ± 0.2 4.7 ± 1.2 2.5 ± 0.5*   
C57BL/6NTac  m  10 3.7 ± 0.4 4.8 ± 0.4 3.0 ± 0.4   
          
          
rs13478783 
(Snca) 
6 f homo (G/G) 46 3.9 ± 0.6 2.3 ± 1.0 2.1 ± 0.8 6.3 ± 4.7* 0.67 ± 0.45
  het (G/A) 53 3.7 ± 0.4 2.6 ± 0.9 2.1 ± 0.6 8.8 ± 5.1 0.69 ± 0.39
rs13481014 
 
11 f homo (C/C) 51 3.8 ± 0.6 2.6 ± 1.0 2.2 ± 0.7 8.8 ± 5.6* 0.68 ± 0.38
  het (C/T) 46 3.8 ± 0.4 2.4 ± 0.9 2.1 ± 0.7 6.4 ± 4.2 0.68 ± 0.46
          
allele 
combination 
 f beneficial 24 3.9 ± 0.5 2.3 ± 1.1 2.0 ± 0.8 6.0 ± 4.4 0.59 ± 0.33*
  risk 29 3.7 ± 0.3 2.8 ± 0.6 2.3 ± 0.6 9.0 ± 5.7 0.67 ± 0.37
          
C57BL/6JRj  f  6 4.4 ± 0.1* 1.5 ± 0.7* 1.8 ± 0.5*   
C57BL/6NTac  f  6 3.9 ± 0.1 2.7 ± 0.9 2.5 ± 0.6   
Data represent means ± SD. *suggestive association between genotype variants (uncorrected p-values at *0.05, **0.01 level). homo: homozygous; het: 
heterozygous; epi: epigonadal; sc: subcutaneous. beneficial allele combination: male mice:(C/C) of rs13480122 and (C/T) of rs13481014; female mice: (G/G) for 
rs13478783 and (C/C) for rs4165065; risk allele combination: male mice: (C/T) for rs13480122 and (C/C) for rs13481014; female mice: (G/A) for rs13478783 and 
(C/T) for rs4165065. 
 
Table 3. Univariate correlations between human SNAP29  mRNA expression and 
parameters of obesity, fat distribution, glucose and lipid metabolism and adipokines.  
 SC SNAP29
(r; p-value) 
after adjustment for 
age, gender and BMI 
Age (years) 0.128; 0.051  
Visceral fat area (cm²) -0.217; 0.002  
SC fat area (cm²) -0.265; <0.001  
CT ratio 0.204; 0.004 0.191; 0.032 
Body weight (kg) -0.043; 0.514  
BMI (kg/cm²) -0.267; <0.001  
WHR -0.099; 0.131  
Waist (cm) -0.268; <0.001  
Hip (cm) -0.063; <0.001  
% body fat -0.241; 0.002  
HbA1c (%) -0.107; 0.112  
Fasting plasma glucose (mmol/l) -0.052; 0.433  
Fasting plasma insulin (pmol/l) -0.211; 0.005  
2h OGTT (mmol/l) 0.022; 0.833  
Glucose infusion rate (mg/kg/min) -0.017; 0.870  
Total cholesterol (mmol/l) -0.155; 0.072  
HDL-cholesterol (mmol/l) 0.075; 0.394  
LDL-cholesterol (mmol/l) -0.235; 0.010  
Triglyceride (mmol/l) 0.055; 0.514  
FFA (mmol/l) -0.161; 0.041  
hsCrp (mmol/l) -0.044; 0.522  
Serum leptin (pg/ml) -0.258; 0.001  
Serum adiponectin (g/ml) 0.111; 0.149  
IL-6 (pg/ml) -0.147; 0.056  
SC, subcutaneous; corrected P values <0.01 were considered significant (bold); r, 
Spearman´s correlation coefficient. 
 
 
Table 4. Anthropometric and metabolic characteristics of the study groups. (n=234).  
 
 Male 
(N=84) 
Female 
(N=150) 
Age (years) 53 ± 14 49 ± 15
Visceral fat area (cm²) 251 ± 170 250 ± 178
SC fat area (cm²) 1034 ± 819 1256 ± 779
CT ratio 0.53 ± 0.70 0.33 ± 0.42*
Body weight (kg) 125 ± 48 116 ± 39
BMI (kg/cm²) 39 ± 13 42 ±13
Waist (cm) 128 ± 35 117 ± 29**
Hip (cm) 128 ± 35 129 ± 28
WHR 0.99 ± 0.10 0.90 ± 0.09***
Body fat (%) 33.8 ± 13.7 37.8 ± 10.1
HbA1c (%) 6.0 ± 0.9 5.9 ± 1.0
FPG (mmol/l) 6.3 ± 1.7 5.9 ± 1.6
FPI (pmol/l) 97 ± 121 75 ± 94
2h OGTT (mmol/l) 7.0 ± 2.8 6.8 ± 2.8
Clamp (mg/kg/min) 71.4 ± 37.1 81.4 ± 29.3
Total cholesterol (mmol/l) 4.9 ± 1.0 5.0 ± 0.9
HDL-cholesterol (mmol/l) 1.2 ± 0.3 1.4 ± 0.4*
LDL-cholesterol (mmol/l) 3.2 ± 0.9 3.0 ± 0.8
Triglyceride (mmol/l) 1.8 ± 1.1 1.4 ± 0.7**
Free fatty acids (mmol/l) 0.53 ± 0.40 0.50 ± 0.42
Serum leptin (pg/ml) 22.4 ± 15.9 42.3 ± 21.3***
Serum adiponectin (g/ml) 6.4 ± 4.3 7.9 ± 4.7
IL-6 (pg/ml) 5.9 ± 6.4 6.7 ± 5.0
Data are means ± SD, statistically significant differences between genders at p-value * < 
0.05, ** < 0.01; *** < 0.001 
 
 
 
